NBRV vs. TIL, OGI, CYBN, NVCT, SPRO, NLTX, IPHA, LRMR, ALTS, and VYGR
Should you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Instil Bio (TIL), Organigram Global (OGI), Cybin (CYBN), Nuvectis Pharma (NVCT), Spero Therapeutics (SPRO), Neoleukin Therapeutics (NLTX), Innate Pharma (IPHA), Larimar Therapeutics (LRMR), ALT5 Sigma (ALTS), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry.
Nabriva Therapeutics vs. Its Competitors
Nabriva Therapeutics (NASDAQ:NBRV) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.
Nabriva Therapeutics has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Instil Bio has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500.
Instil Bio has a consensus target price of $119.00, indicating a potential upside of 399.79%. Given Instil Bio's stronger consensus rating and higher possible upside, analysts plainly believe Instil Bio is more favorable than Nabriva Therapeutics.
Instil Bio has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Instil Bio's return on equity of -45.52% beat Nabriva Therapeutics' return on equity.
In the previous week, Instil Bio had 4 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 4 mentions for Instil Bio and 0 mentions for Nabriva Therapeutics. Instil Bio's average media sentiment score of 0.94 beat Nabriva Therapeutics' score of 0.00 indicating that Instil Bio is being referred to more favorably in the news media.
0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by insiders. Comparatively, 47.2% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Instil Bio beats Nabriva Therapeutics on 13 of the 16 factors compared between the two stocks.
Get Nabriva Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nabriva Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NBRV) was last updated on 7/3/2025 by MarketBeat.com Staff
Free NBRV Stock Alerts